Pre Diabetic
Conditions
Brief summary
Prediabetes is a metabolic condition associated with increased risk of type 2 diabetes and cardiovascular disease. Intermittent fasting (IF) has emerged as a potential dietary intervention to improve metabolic health, yet comparative evidence among different IF patterns remains limited. This randomized controlled trial aims to evaluate the effects of three intermittent fasting regimens-5:2 fasting, alternate-day fasting, and time-restricted feeding-compared with a control diet on metabolic parameters, inflammatory markers, body composition, and nutrigenomic profiles in adults with prediabetes.
Interventions
BEHAVIORALDiet
Intermittent Fasting
Sponsors
Muhammad Aron Pase
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
25 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with prediabetes, defined according to ADA criteria (fasting plasma glucose 100-125 mg/dL or 2-hour postprandial glucose 140-199 mg/dL). 2. Willing to follow the fasting/diet intervention protocol for 4-6 weeks (depending on the study duration). 3. Signing informed consent and willing to be randomized into one of 3 intervention groups (Monday-Thursday Fasting/5:2, Alternate-Day Fasting/ADF, or Time-Restricted Fasting/IF).
Exclusion criteria
1. Diagnosis of type 2 diabetes mellitus. 2. Currently undergoing antidiabetic drug therapy (e.g., metformin, sulfonylurea, insulin). 3. Has a severe chronic disease (kidney failure, liver failure, heart failure, or eating disorder). 4. Pregnancy or breastfeeding. 5. History of eating disorders (anorexia nervosa, bulimia nervosa, or binge eating disorder). 6. Taking medications that affect glucose metabolism (e.g., systemic steroids, atypical antipsychotics, etc.). Diagnosis of type 2 diabetes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metabolic Profile | Baseline, Week 3, and Week 6 | Change in Fasting Plasma Glucose (mg/dL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Lipid Profile | Baseline and Week 6 | Concentration Changes of Total Cholesterol |
| Nutrigenomics | Baseline | Distribution of Fat Mass and Obesity-Associated gene polymorphism with Enzyme-Linked Immunosorbent Assay method |
| Body Composition | Baseline, Week 3, and Week 6 | Change in BMI |
| Inflammation Profile | Baseline and Week 6 | Concentration Changes of inflammatory marker (CRP) |
Countries
Indonesia
Contacts
CONTACTMuhammad Aron Pase, MD
Outcome results
None listed